New Study Shows Early Aggressive Treatment for Crohn’s Disease Leads to Better Long-Term Outcomes

For people living with Crohn’s disease, a chronic inflammatory bowel condition that can cause severe abdominal pain, diarrhea, and fatigue, the question of when to start powerful medications has long been a difficult one. Doctors have traditionally used a cautious “step-up” approach, starting with milder drugs and only moving to stronger treatments if symptoms worsened. But new long-term data from a major clinical trial called PROFILE suggests that flipping this strategy on its head—using the most effective drugs right from the start—may dramatically improve patients’ lives for years to come.

Presented at the annual Digestive Disease Week meeting, the five-year follow-up results show that a “top-down” approach, which involves early aggressive therapy with the TNF inhibitor infliximab (brand name Remicade) plus an immunomodulator, significantly reduced the need for abdominal surgeries, hospitalizations, and disease progression compared with the conventional step-up method. The findings offer some of the strongest evidence yet that early, powerful treatment can actually change the course of Crohn’s disease, not just manage its symptoms.

Why This Matters for People with Crohn’s Disease

Crohn’s disease affects an estimated 3 million adults in the United States alone. It is a lifelong condition in which the immune system mistakenly attacks the lining of the digestive tract, causing inflammation that can lead to ulcers, strictures (narrowing of the intestine), and fistulas (abnormal connections between organs). Many patients experience unpredictable flare-ups that disrupt work, school, and social life. The goal of treatment has always been to reduce inflammation, maintain remission, and prevent complications. But until now, doctors have debated whether starting with the strongest drugs immediately—rather than saving them for later—is worth the potential risks and costs.

The PROFILE trial, conducted at 40 hospitals and clinics across the United Kingdom from 2017 to 2022, provides a clear answer: early aggressive therapy not only works better but also appears safer over the long haul.

Key Findings from the Five-Year PROFILE Follow-Up

The study randomized 386 adults newly diagnosed with active Crohn’s disease to either a top-down strategy (immediate treatment with infliximab plus an immunomodulator) or a conventional step-up strategy (gradually increasing treatment intensity until flare-ups are controlled). After the initial 48-week study period, patients were managed according to local standards of care, and researchers tracked their health for a median of about 3.7 years (1,352 days) from diagnosis.

Here are the most striking results:

– Abdominal surgeries related to Crohn’s disease: Only 6 surgeries occurred in the top-down group, compared with 28 in the step-up group. This represents a more than fivefold higher risk of surgery for those on the step-up approach (adjusted hazard ratio 5.23, 95% confidence interval 1.99-13.76).

– Disease progression to complicated forms (B2/B3): Patients on step-up therapy were nearly 2.5 times more likely to develop stricturing or penetrating disease, which often requires surgery or more intensive treatment (adjusted hazard ratio 2.46, 95% CI 1.25-4.86).

– Hospital admissions (excluding surgeries): The step-up group had 56 hospitalizations, while the top-down group had 34—a twofold higher risk (adjusted hazard ratio 2.01, 95% CI 1.18-3.41).

These numbers tell a powerful story: starting with the most effective therapy early can prevent the worst complications of Crohn’s disease.

What Experts Say About This Approach

“We think this is probably the most robust evidence to date that it is possible to modify the course of Crohn’s disease,” said Dr. Nurulamin Noor, a gastroenterologist and researcher at the University of Cambridge who presented the findings. “The key thing is to initiate early effective therapy as soon as possible after diagnosis. This is something we’ve suspected for quite a while, but the 5-year follow-up data from PROFILE helps support this.”

Dr. Noor emphasized that the benefits are not just short-term. “I think knowing this not only leads to short-term benefit, but long-term benefit and long-term gains, is really helpful for discussions between patients and clinicians,” he added.

How the Early Results Compared

The original PROFILE results, published in 2024, had already shown impressive short-term outcomes. At 48 weeks:

– Sustained remission (without steroids or surgery) was achieved in 79% of the top-down group, compared with just 15% of the step-up group (P <0.0001).

• Endoscopic remission (healing of the intestinal lining visible during a scope) occurred in 67% of the top-down group versus 44% of the step-up group (P <0.0001).

These findings were so dramatic that many experts considered them practice-changing. The five-year data now confirm that the early benefits are not lost over time.

Safety: A Surprising Advantage of Early Aggressive Therapy

One of the biggest concerns with powerful immunosuppressive drugs like infliximab is the potential for serious side effects, including infections and malignancies. Many doctors have hesitated to use them early for fear of exposing patients to unnecessary risk.

But the PROFILE trial found the opposite. At 48 weeks, the top-down group experienced:

• Fewer total adverse events (168 vs. 315)
• Fewer serious adverse events (15 vs. 42)
• Fewer complications requiring surgery (1 vs. 10)

In the long-term analysis, the rates of serious infections and malignancies were similar between the two groups. About 8% of patients in the top-down group developed serious infections versus 7% in the step-up group. Malignancies were reported in 2% and 3%, respectively—a difference that is not statistically significant.

“Our data suggest that not only is it more effective to treat with the most effective medications as soon as possible, it’s actually safer for patients,” Dr. Noor noted.

The Cost Factor: Does Early Aggressive Therapy Save Money?

Many patients and healthcare systems worry about the high cost of biologic drugs like infliximab. However, Dr. Noor’s team also conducted a cost-effectiveness analysis using PROFILE data. The results showed that the extra upfront cost of top-down therapy is “more than offset by the fact you reduce hospital admissions, you reduce surgeries, you reduce visits to GPs, you reduce phone calls from patients to IBD helplines and IBD nurses,” he said.

In other words, preventing complications saves money in the long run—for both healthcare systems and patients.

What This Means for Readers

If you or a loved one has been diagnosed with Crohn’s disease, these findings offer important guidance for conversations with your gastroenterologist. Key takeaways include:

• Early, powerful treatment may change the course of your disease. Instead of waiting for symptoms to worsen, starting with a top-down approach could prevent surgeries and hospitalizations.
• Safety concerns should not be a barrier. The data suggest that early use of infliximab plus an immunomodulator is not associated with higher rates of serious infections or cancer over five years.
• Cost should not deter you. While biologic drugs are expensive, the overall healthcare costs may be lower when you factor in fewer emergencies and procedures.
• Discuss your options openly. Not every patient is a candidate for top-down therapy, and individual factors like disease location, severity, and personal preferences matter. But the evidence now strongly supports considering this approach early.

Practical Steps for Patients

If you are newly diagnosed or considering a treatment change, here are some steps to take:

1. Ask your doctor about the PROFILE trial. Mention that you are aware of the five-year data supporting early aggressive therapy.

2. Understand your disease severity. Top-down therapy may be most beneficial for patients with moderate to severe Crohn’s disease.

3. Discuss monitoring for side effects. While the study found no increased risk of serious infections or malignancies, regular blood tests and check-ups are still important.

4. Consider a second opinion. If your doctor is hesitant about a top-down approach, a specialist at an academic medical center or IBD center may have more experience with this strategy.

5. Look into insurance coverage. Many insurance plans now cover biologic therapies for Crohn’s disease, especially when prescribed early.

The Bottom Line

The PROFILE trial’s five-year follow-up provides compelling evidence that early aggressive treatment with infliximab plus an immunomodulator can fundamentally alter the course of Crohn’s disease, reducing surgeries, hospitalizations, and disease progression—all without increasing long-term safety risks. For patients, this means a real chance at a better quality of life, fewer emergency room visits, and more time spent in remission.

As Dr. Noor put it: “Using effective therapies earlier is not only safer for patients, it is cheaper for healthcare services and payers.” For anyone living with Crohn’s disease, this is news worth discussing with your healthcare team today.

Source: MedPage Today